Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NGM Biopharmaceuticals has appointed William Rieflin as the new CEO and has also been named as one of the board of directors of the company.
Subscribe to our email newsletter
Prior to joining NGM Biopharmaceuticals, Rieflin was the president of XenoPort, and currently serves on XenoPort’s board of directors.
NGM Biopharmaceuticals chairman David Goeddel said that they are delighted that Bill will be leading NGM in the next phase of its evolution. Bill’s experience building companies is the perfect match for NGM’s exceptional team and promising technology.
Rieflin said that he is excited by the prospect of leading a team with a great chance of discovering the next generation of novel therapies to treat the unmet needs of patients with metabolic diseases.
NGM Biopharmaceuticals is a drug discovery and development company dedicated to developing transformational medicines that significantly improve human health.